Roche cuts bait on late-stage study of Hunt­ing­ton's med tomin­ersen, an Io­n­is im­port with pri­or safe­ty flags

Hop­ing to tack­le the ab­solute­ly bru­tal Hunt­ing­ton’s dis­ease, Roche inked a li­cens­ing pact with Io­n­is back in 2017 for a nov­el an­ti­sense ther­a­py tar­get­ing a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER